Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms × BCG Vaccine × Genitourinary × Clear all

Non-Muscle Invasive Bladder Neoplasms

NCT04165317 2026-01-22

CREST

Phase 3 Active not recruiting

1,068 enrolled 20 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2025-11-25

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

31 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT05981131 2025-03-13

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active not recruiting

6 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Phase 2 Completed

120 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05332353 2022-04-18

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Unknown

100 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT01498172 2015-02-04

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Phase 1 Completed

23 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00330707 2011-03-04

Combined Use of BCG and Interferon Alpha in Bladder Cancer

Phase 2/3 Completed

140 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Clinical Trials

BRIDGE

CREST

POTOMAC

BCG-TIME

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Combined Use of BCG and Interferon Alpha in Bladder Cancer